Navigation Links
Blood pressure enzyme can have tumor-sensing role
Date:4/7/2008

By increasing production of a blood pressure-regulating enzyme in mice, researchers have found they can enhance the mouse immune system's ability to sense tumor growth.

When scientists at Emory University School of Medicine engineered mice that make more angiotensin-converting enzyme in white blood cells called macrophages, the mice could more effectively limit the growth of injected tumors.

The enzyme works by "trimming" small bits of protein that originate from the tumors, allowing the immune system to identify the tumors and mount a response more efficiently.

The results are published online in the Journal of Biological Chemistry (JBC).

Senior author Kenneth Bernstein, MD, Emory distinguished service professor of pathology and laboratory medicine, says his group's findings suggest a strategy for amplifying immune system function in humans.

"We think we've discovered a means of tweaking the immune response by modifying the process of antigen presentation," Dr. Bernstein says.

In the clinic, doctors might be able to enhance a cancer patient's ability to resist a tumor by removing his or her white blood cells, boosting their production of angiotensin-converting enzyme, and re-infusing them, he says.

Antigen presentation refers to how proteins from within the body are constantly recycled and chewed up into small bits called peptides, which appear on the surfaces of cells. While the immune system generally ignores peptides from proteins in the body, it can respond to the peptides from foreign invaders.

Angiotensin-converting enzyme, or ACE, plays a critical role in controlling blood pressure and is the target of common medications. The hormone angiotensin (a peptide) constricts blood vessels, increases the brain's perception of thirst and indirectly causes the kidneys to retain sodium, thus limiting its production can reduce blood pressure.

ACE acts chemically by removing amino acids, the building blocks of proteins, from one end of a larger protein. In the body, ACE converts an inactive form of angiotensin into an active form by clipping off two amino acids.

But angiotensin is not ACE's only target. In previous studies, Bernstein and his co-workers found that manipulating its activity also affects processes such as fertility and the generation of red blood cells in the bone marrow.

To dissect out ACE's role in the immune system, they created mice with a genetic alteration in the ACE gene, forcing the gene to be turned on only in macrophages.

Macrophages are especially good at displaying peptides on their surfaces to other white blood cells called T cells so that the T cells are stimulated to grow. The T cells in turn kill virally infected cells. Depending on the situation, they can sometimes kill tumor cells as well.

When injected with several types of melanoma or lymphoma, the altered mice developed smaller tumors than normal mice. The tumors they did have contained more white blood cells attacking the cancerous cells.

In the JBC paper, the researchers show that ACE boosts cells' ability to display some foreign peptides, increasing their ability to stimulate T cells by several-fold.

Bernstein cautions that normally, macrophages make little ACE, so its effects must be seen as artificial. He notes that ACE inhibitors such as enalapril and lisinopril are taken by millions of people with high blood pressure and have not been reported to weaken the immune system.

However, cells similar to macrophages have been shown to produce ACE in response to pathogens such as sarcoid or leprosy, he says.


'/>"/>

Contact: Holly Korschun
hkorsch@emory.edu
404-727-3990
Emory University
Source:Eurekalert

Related medicine news :

1. Specific antagonism lowers blood pressure
2. Restricting Blood Flow May Help Heart Bypass Patients
3. FDA Updates Prescription Guidelines for Blood Thinner
4. Doctors Often Miss High Blood Pressure in Kids
5. Back to School Means Return of School Blood Drives
6. Blood-flow detector software show promise in preventing brain damage
7. FDA Approves New Roche West Nile Virus Blood Screening Test
8. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
9. Laser blasts viruses in blood
10. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
11. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... Sharon Kleyne, host of the nationally syndicated radio ... on Voice of America, declared on her radio program in November 2016 the need ... when these bullies attack leaders in corporate America, they are trying to take advantage ...
(Date:12/7/2016)... ... December 07, 2016 , ... 1105 Media’s Live ... the Folio: Marketing Awards competition. Live From won in the Use of Social ... and ultimately successful projects undertaken by the media industry’s most innovative marketing professionals. ...
(Date:12/7/2016)... ... December 07, 2016 , ... Maureen McLaughlin, LA.c., a ... Medicine Associates of Connecticut (RMACT). McLaughlin brings nearly 20 years of experience with ... help patients realize their family building goals. Acupuncture helps fertility patients ...
(Date:12/7/2016)... NORFOLK, Va. (Dec. 3, 2016) , ... (PRWEB) ... ... the nation’s only patient advocacy nonprofit for individuals impacted by cerebral cavernous angiomas, ... work in New Mexico with a patient engagement program. New Mexico has more ...
(Date:12/6/2016)... ... December 06, 2016 , ... People ... can be seen on a type of MRI, according to a study appearing ... of the central nervous system characterized by tremors or trembling and stiffness in ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... Dec. 6, 2016   AlloSource , one ... bone, skin and soft-tissue allografts for use in ... Process Manager, for being named to the Board ... Quality Award by the Commerce Department,s National Institute ... commitment to process excellence. The Baldrige Award is ...
(Date:12/6/2016)... , Dec. 6, 2016   ... clinical-stage medical dermatology and aesthetics company, today ... privately held specialty pharmaceutical company focused on ... skin conditions, including psoriasis, atopic dermatitis and ... agreement, Sienna will make an undisclosed upfront ...
(Date:12/6/2016)... 6, 2016  Blueprint Medicines Corporation (NASDAQ: ... kinase medicines for patients with genomically defined diseases, today ... of $125,000,000 million in shares of its common stock. ... a 30-day option to purchase up to an additional ... in connection with the public offering. All shares of ...
Breaking Medicine Technology: